NCT05193721View on ClinicalTrials.gov

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

August 31, 2024

Conditions
Advanced Malignant Tumors
Interventions
DRUG

SHR-1901

SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg

Trial Locations (1)

200433

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY